Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- RNAi discovery
- Discovery of siRNA and its function in mammals
- siRNA basics
- siRNA unique position in drug development
- siRNA critical issues
- Delivery
- Delivery: efficiency vs. toxicity
- Efficacy
- Efficacy: hit rate with random siRNA
- Efficacy: RISC selectivity
- Efficacy: siRNA rational design
- Specificity
- siRNAs may produce off-target silencing
- Wound-healing assay (1)
- Off-targeting might yield false phenotypes
- Off-target issues with siRNAs
- BLAST filter
- Smith-Waterman alignment algorithm
- Testing Smith-Waterman alignment algorithm
- Alignment of detected and predicted off-targets
- Preliminary conclusions
- Different look at off-targeting issues
- miRNA targeting
- Testing potential miRNA effects: workflow
- Seed target sequence occurrence
- Off-target issues with siRNAs
- Bioinformatics utilization
- Modulate siRNA effective concentration
- Nature's use of siRNA dilution phenomenon
- Controlled siRNA pooling in mammalian cells
- Wound healing assay (2)
- siRNA number 1 and 2 controlled pooling example
- siRNA number 2 and 4 controlled pooling example
- siRNA applications
- Controlled pooling example
- Chemical modifications on siRNA
- Antisense strand modifications reduce off-targets
- Chemical modification example I
- Chemical modification example II
- Pooling of chemically modified molecules
- Specificity: conclusions
- siRNA key technological issues: summary
- Acknowledgements
Topics Covered
- General outline of RNAi technology
- Basic principles and mechanisms of RNAi
- RNAi technological aspects, delivery, activity and specificity of RNAi compounds
- Key factors defining RNAi application
- Test system
- Target throughput
- Phenotypic readout
Talk Citation
Samarsky, D. and Faherty, C. (2015, October 14). RNAi: key technological aspects [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 7, 2024, from https://doi.org/10.69645/WJHU7106.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Dmitry Samarsky has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
- Dr. Ciaran Faherty has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Methods
Transcript
Please wait while the transcript is being prepared...
0:00
Welcome to today's discussion on RNAi key technological aspects.
0:06
In brief, RNAi is a sequence-specific knockdown of
genes at the messenger RNA level by double-stranded RNA.
The ability of the double-stranded RNA to knock down
genes of interest was first described by Craig Mello,
Andrew Fire, and co-workers in 1998.
This phenomenon was observed in the nematode C. elegans where
the long double-stranded RNA could be administered by direct injection,
soaking of worms in an RNA solution or by
feeding them with bacteria expressing complimentary RNA strands.
0:40
Early experiments that were aimed at defining
the RNAi mechanisms revealed that in animal cells,
long double-stranded RNA are not the RNAi triggering agents per say.
Inside the cell, these molecules,
the long double-stranded RNA,
become a substrate for the enzyme called Dicer.
Dicer cleaves the initial long double-stranded RNA into smaller RNA species,
usually between 21 and 25 base pairs.
And then, refer to a short interfering RNAs or siRNAs,
composed of a sense and antisense strand.
The antisense strand, often referred to as the guide strand of the siRNA,
becomes incorporated into the RNA induced silencing
complex or RISC which performs a cleavage of the desired target,
the messenger RNA transcript of interest.
Being fully cognizant of the biological role and their ability
to avoid adverse cell death due to the short length,
Thomas Tuschi and co-workers tested chemically synthesized siRNA molecules in
mammalian cells and demonstrated for the first time
their potent inhibition of the targeted gene in this model system.
This discovery triggered the widespread use of RNAi indeed by specifically
knocking down a single gene and monitoring
the corresponding phenotype in the mammalian system.
It has become possible to assign functions to those genes.
When we consider the RNAi mechanism and its application to study in biological processes,